EUVIMEDEUVIMED entdecken
Crossref

Effectiveness and Safety of Retreatment with 177 Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States

Ebrahim S Delpassand, Soheil M Yazdi, Shashank Ghantoji, Antonio Nakasato, Corinne Strickland, Rodolfo Nunez, Afshin Shafie, Susan Cork, Clare Byrne, Jackson Tang, Jeetvan Patel

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.265703 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Ebrahim S Delpassand und 10 weiteren Autor:innen. Beteiligte Einrichtung: Excel Diagnostics and Nuclear Oncology Center, Houston, Texas. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Disease Progression. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced neuroendocrine tumors (NETs) are associated with a poor prognosis. A regimen of 4 cycles of 177Lu-DOTATATE has been shown to improve both progression-free survival (PFS) and overall survival (OS) in patients with advanced NETs. To the best of our knowledge, this is the first study in the United States to evaluate the effectiveness and safety of additional cycles of 177Lu-DOTATATE therapy in patients with progressive NETs.

Methods

This was a retrospective chart review of adults with advanced NETs. The patients had undergone initial treatment with up to 4 cycles of 177Lu-DOTATATE and, after disease progression and a period of at least 6 mo since the end of the initial treatment, were retreated with at least 1 additional cycle at a single center (2010-2020). Patient characteristics, treatment patterns, and clinical outcomes were evaluated descriptively. Response was evaluated according to RECIST 1.1; toxicity was defined using criteria from Common Terminology Criteria for Adverse Events, version 5.0. Kaplan-Meier plots were used to evaluate PFS and OS.

Results

Of the 31 patients who received 177Lu-DOTATATE retreatment, 61% were male and 94% were White. Overall, patients received a median of 6 cycles (4 initial cycles and 2 retreatment cycles), and the mean administered activity was 41.9 GBq. Two patients also went on to receive additional retreatment (1 and 2 cycles, individually) after a second period of at least 6 mo and progression after retreatment. Best responses of partial response and stable disease were observed in 35% and 65% of patients after the initial treatment and 23% and 45% of patients after retreatment, respectively. The median PFS after the initial treatment was 20.2 mo and after retreatment was 9.6 mo. The median OS after the initial treatment was 42.6 mo and after retreatment was 12.6 mo. Hematologic parameters decreased significantly during both the initial treatment and retreatment but recovered such that there was little difference between the values before the initial treatment and before the retreatment. Clinically significant hematotoxicity occurred in 1 and 3 patients after the initial treatment and retreatment, respectively. No grade 3 or 4 nephrotoxicity was observed.

Conclusion

Retreatment with 177Lu-DOTATATE after progression appeared to be well tolerated and offered disease control in patients with progressive NETs after initial 177Lu-DOTATATE treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotideOrganometallic CompoundsDisease ProgressionHumansMaleRetrospective StudiesFemaleMiddle AgedUnited StatesAgedTreatment OutcomeAdultRetreatmentSafetyAged, 80 and over

Stichwörter der Autor:innen

177Lu-DOTATATEadvanced neuroendocrine tumorspeptide receptor radionuclide therapyreal-world outcomesretreatment

Substanzen

lutetium Lu 177 dotatateOctreotideOrganometallic Compounds

Autor:innen und Institutionen

  • Excel Diagnostics and Nuclear Oncology Center, Houston, Texas.
  • Novartis Pharmaceuticals Corp., East Hanover, New Jersey; and.
  • Asclepius Analytics, New York, New York.
  • Novartis Pharmaceuticals Corp., East Hanover, New Jersey; and jeetvan.patel@novartis.com.

Zitieren

APA

Delpassand, E. S., Yazdi, S. M., Ghantoji, S., Nakasato, A., Strickland, C., Nunez, R., Shafie, A., Cork, S., Byrne, C., Tang, J., & Patel, J. (2024). Effectiveness and Safety of Retreatment with 177 Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.265703

Vancouver

Delpassand ES, Yazdi SM, Ghantoji S, Nakasato A, Strickland C, Nunez R, et al. Effectiveness and Safety of Retreatment with 177 Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.265703

BibTeX
@article{Delpassand2024,
  author = {Delpassand, Ebrahim S and Yazdi, Soheil M and Ghantoji, Shashank and Nakasato, Antonio and Strickland, Corinne and Nunez, Rodolfo and Shafie, Afshin and Cork, Susan and Byrne, Clare and Tang, Jackson and Patel, Jeetvan},
  title = {Effectiveness and Safety of Retreatment with 177 Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.265703}
}
Kostenlos starten →